Pancreatic Cancer Pain Management

Introduction to Pain Management

The American Society of Clinical Oncology recommends a stepwise approach to pain management in pancreatic cancer, starting with non-opioid analgesics, progressing to opioids, and incorporating neurolytic celiac plexus block early in the disease course for optimal pain control and quality of life 1, 2

The World Health Organization recommends beginning with non-opioid analgesics such as acetaminophen/paracetamol or NSAIDs for mild pain (WHO level I) 3, 4
For moderate pain (WHO level II), the European Society for Medical Oncology suggests adding weak opioids like codeine, dihydrocodeine, or tramadol; alternatively, low doses of strong opioids may be used, especially if progressive pain is anticipated 4, 5
For severe pain (WHO level III), the National Comprehensive Cancer Network recommends using strong opioids such as morphine (oral preferred), hydromorphone, or oxycodone in both immediate and modified-release formulations 3, 4
The European Association for Palliative Care advises titrating opioid doses rapidly to achieve effective pain control 5
The American Pain Society suggests providing around-the-clock dosing with additional "breakthrough" doses (typically 10% of total daily dose) for transient pain exacerbations 3
The American Society of Clinical Oncology recommends adjusting baseline opioid regimen if more than four breakthrough doses are needed daily 5

The European Society of Gastrointestinal Endoscopy recommends considering neurolytic celiac plexus block (NCPB) early in the disease course rather than as a last resort 7, 2
Randomized controlled trials show NCPB provides a larger initial decrease in pain compared to systemic analgesic therapy alone, and longer-lasting pain relief (up to 6 months) 2, 8, 9
The American Gastroenterological Association suggests NCPB can be performed via percutaneous, laparoscopic, endoscopic, or open surgical approaches 7, 9

The National Comprehensive Cancer Network recommends assessing pain at every clinic visit using validated tools such as visual analog scales 3, 4
The American Society of Clinical Oncology suggests combining pharmacological management with non-pharmacological approaches 3
The European Association for Palliative Care advises addressing psychological aspects of pain with appropriate interventions for depression and anxiety, which are common in pancreatic cancer patients 7, 8